Mel Mann shares his inspiring 30-year journey with chronic myeloid leukemia, from a terminal diagnosis to long-term survival.

Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in ...

Kolibaba, KS, Druker BJ. Current Status of Treatment for Chronic Myelogenous Leukemia. MedGenMed 2(2), 2000 [formerly published in Medscape Hematology-Oncology eJournal 3(2), 2000]. Available at ...

(IN BRIEF) Novartis has announced promising 96-week results from the Phase III ASC4FIRST trial, showcasing Scemblix® (asciminib) as a superior treatment for newly diagnosed Philadelphia ...

Chronic myeloid leukemia (CML) starts in the myeloid cells in the ... Depending on the type of leukemia, early diagnosis and treatment are important for a better prognosis and more varied ...

Opens in a new tab or window The rare hematologic malignancy known as chronic myelomonocytic leukemia ... in CML are unclear. A new study found that mutations in activated signaling and myeloid ...

(IN BRIEF) Novartis has announced promising 96-week results from the Phase III ASC4FIRST trial, showcasing Scemblix® (asciminib) as a superior treatment for newly diagnosed Philadelphia ...

Updated 96-week data from the ASC4FIRST trial show asciminib significantly outperforms standard TKIs in major molecular ...